Tsinghua University

Gp Medical, Inc.

Kiran Sonaje

Hosheng Tu

Hsing-Wen Sung

Er-Yuan Chuang

Ho-Ngoc Nguyen

Ha Giang Thi Nguyen

Zi-Xian Liao

Fang Yi Su

The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for oral drug delivery.

Pharmaceutical composition of nanoparticles

The invention discloses a pharmaceutical composition of bioactive nanoparticles composed of chitosan, poly-glutamic acid, and a bioactive agent for oral delivery. The chitosan-based nanoparticles are characterized with a positive surface charge and enhanced permeability for drug delivery.

The invention discloses a composition of chitosan-shelled nanoparticles and methods of manufacturing. The chitosan-shelled nanoparticles are characterized with a positive surface charge and enhanced epithelial permeability for oral drug delivery.

The invention discloses a composition of chitosan-shelled nanoparticles and methods of manufacturing. The chitosan-shelled nanoparticles are characterized with a positive surface charge and enhanced epithelial ermeability for oral drug delivery.

The invention relates to a pharmaceutical composition of nanoparticles, wherein the nanoparticles comprise positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and at least one bioactive agent for treating diabetes of an animal subject.

The invention relates to a method for treating disorders or diseases of a tight junction comprising delivering a pharmaceutical composition of nanoparticles to the tight junction, wherein the nanoparticles consist of positively charged chitosan, a negatively charged substrate, optionally a zero-charge compound, and at least one bioactive agent for treating said disorders or diseases of the tight junction of an animal subject.

The invention discloses nanoparticles composed of chitosan, poly-glutamic acid, and at least one bioactive agent, wherein the bioactive agent may include mitofusin 1, mitofusin 2, and/or anti-diabetic compounds.

The invention relates to a method of managing a tumor of an animal subject comprising imaging the tumor by delivering a dosage of imaging nanoparticles to the tumor site, the imaging nanoparticles consisting of positively charged chitosan, optionally a zero-charge substance or bioactive agent, and a negatively charged substrate having gadolinium (Gd) chelated to the negatively charged substrate.

Composition of imaging nanoparticles

Pharmaceutical composition of nanoparticles for protein drug delivery

The invention relates to a method of co-administering a peptide or protein drug with an enzyme-resistant PGA-complexone compound orally so to mitigate enzyme attack in the gastrointestinal tract of an animal subject.

Growing community of inventors

Hsinchu, Taiwan

Kiran Sonaje